2016感染性休克的急诊处理规.pptVIP

严重感染/感染性休克 急诊处理规范 感染相关概念 7.正性肌力药物治疗 35 30 25 20 15 10 5 0 30.8% 24.7% Placebo (n-840) Drotrecogin alfa (activated) (n=850) Mortality (%) 6.1% absolute reduction in mortality Results: 28-Day All-Cause Mortality Primary analysis results 2-sided p-value 0.005 Adjusted relative risk reduction 19.4% Increase in odds of survival 38.1% Adapted from Table 4, page 704, with permission from Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709 Evaluation only. Created with Aspose.Slides for .NET 3.5 C